BidaskClub downgraded shares of Medidata Solutions (NASDAQ:MDSO) from a strong-buy rating to a buy rating in a report issued on Saturday morning, BidAskClub reports.

MDSO has been the subject of a number of other reports. Piper Jaffray Companies downgraded shares of Medidata Solutions from an overweight rating to a neutral rating in a report on Wednesday, June 12th. SunTrust Banks increased their price target on shares of Camden Property Trust to $108.00 and gave the company a buy rating in a report on Thursday, June 13th. William Blair downgraded shares of Medidata Solutions from an outperform rating to a market perform rating in a report on Wednesday, June 12th. Dougherty & Co downgraded shares of Medidata Solutions from a buy rating to a neutral rating in a report on Wednesday, May 1st. Finally, Guggenheim downgraded shares of Medidata Solutions from a buy rating to a neutral rating and set a $92.25 price target for the company. in a report on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. Medidata Solutions currently has a consensus rating of Hold and a consensus target price of $84.24.

Shares of Medidata Solutions stock opened at $90.71 on Friday. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.29. Medidata Solutions has a fifty-two week low of $60.10 and a fifty-two week high of $98.60. The firm has a fifty day moving average of $91.03. The company has a market cap of $5.66 billion, a P/E ratio of 94.49, a PEG ratio of 7.50 and a beta of 1.22.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The firm had revenue of $173.50 million during the quarter, compared to the consensus estimate of $172.12 million. During the same period in the prior year, the firm earned $0.40 EPS. The business’s revenue was up 16.3% on a year-over-year basis. As a group, analysts forecast that Medidata Solutions will post 0.79 earnings per share for the current year.

In other news, Director Robert Taylor sold 3,294 shares of the firm’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $90.88, for a total transaction of $299,358.72. Following the completion of the transaction, the director now directly owns 41,757 shares of the company’s stock, valued at approximately $3,794,876.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC lifted its holdings in shares of Medidata Solutions by 126.8% during the 1st quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 331 shares during the period. Bronfman E.L. Rothschild L.P. increased its position in shares of Medidata Solutions by 26.9% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock worth $87,000 after purchasing an additional 273 shares in the last quarter. Canton Hathaway LLC acquired a new stake in shares of Medidata Solutions during the 1st quarter worth about $109,000. Advisor Group Inc. increased its position in shares of Medidata Solutions by 27.1% during the 4th quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock worth $173,000 after purchasing an additional 545 shares in the last quarter. Finally, World Asset Management Inc acquired a new stake in shares of Medidata Solutions during the 1st quarter worth about $210,000.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.

Further Reading: Derivative

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.